Overview

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Status:
Recruiting
Trial end date:
2026-09-23
Target enrollment:
Participant gender:
Summary
This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
Phase:
Phase 2
Details
Lead Sponsor:
Fox Chase Cancer Center
Collaborator:
Cardinal Health
Treatments:
Cisplatin